Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in neuroendocrine prostate cancer
NCT04702737Phase 1Completed
- Sponsor
- Amgen
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 9
01
Overview
Phase 1, open-label trial of tarlatamab in neuroendocrine prostate cancer (NEPC) (2 arms), sponsored by Amgen. Primary endpoints: Number of Participants Who Experienced One or More Treatment-emergent Adverse Events up to 3 years, Number of Participants Who Experienced One or More Treatment-related Adverse Events up to 3 years and 1 more. Started Jun 2021; status: completed.
02
Drugs
tarlatamab
03
Conditions
neuroendocrine prostate cancer (NEPC)
Beyond the preview
Go deeper on NCT04702737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04702737.